Why it matters
The approval gives eligible U.S. adults a new treatment option for a rare condition. The supplied announcement does not describe the treatment’s availability, cost, or how many patients may use it.
DRUGS, DEVICES & RECALLS • UNITED STATES
FDA approves first plasmid DNA-based immunotherapy for adults with RRP
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a disease that causes growths in the respiratory tract. The agency described it as the first approved plasmid DNA-based immunotherapy.
HOW THIS BRIEF WAS MADE 1 outlet: 1 official. Automated sourcing and summaries by the BLUF engine. Corrections